Supporting first-class drug hunters
Viva Ventures Biotech Fund
We are a VC fund focuses on investments in global first-in-class biotech with significant growth potential, holding periods 70% upto 3 years on average, 30% long period time, the founders having 20+ years drug discovery track record. Viva Ventures is one of very few biotech VCs that have extensive expertise and industry know-how among CVCs.
Started from 1996 for ecosystem building and 1st investment in 2008, Viva Venture Fund I has invested in 9+1* startups with total $23.4 million invested capital out of $25.9 million committed capital.
Supporting Biotech Startups since 2008
Viva Ventures Biotech Fund is backed by the founders of top biotech startups and chief scientists of incubator centers, giving us access to the top startups around the world including Viva Biotech incubators, Boston CIC, and Hong Kong Science Park.
Co-investment Partners
On August 26, 2021, the Hong Kong Innovation and Technology Commission announced that the Innovation and Technology Venture Fund (ITVF) has added Viva Ventures Biotech, LP. as one of the co-investment partners (CPs).
Click to read: Innovation and Technology Venture Fund adds two co-investment partners
Portfolio Companiest
Our Strategies
Our Investment Thesis:
Early Stage = Achieve Superior Return
How to Achieve Higher Success Rate:
Genetic Linkage, Biomarkers and SBDD
Phase 2a/2 Clinical Success Rates
Impact of Structure-Based Drug Design (SBDD)
*Source: Nature Review, Volume 13, June 2014
-
Projects that showed greater confidence in target validation through human genetic target linkage to the disease were less likely to fail owing to a lack of efficacy
-
73% of projects with some genetic linkage of the target to the disease were active or successful in Phase II compared with 43% of projects without such data, also that of projects with biomarkers could exceed 80%
Deal Flow Funnel：To Select Top 2% Deals
Global Ecosystem for Deal Sourcing and Exiting
Global Pharmas and Biotech Companies Include:
Our Portfolio Overview
Diversified Portfolio
Our Team
Fund Management
Jun Mao, PhD (UK)
Honorable President of The University of Hong Kong Foundation
Founder and Chairwoman
-
Founding Director of Viva Biotech, a HK listed company with 100X+ investment return
-
Active biotech investor since 2008, invested 21 biotech and drug discovery startups
-
Working at top tier IB in City of London 1996-2009 after Ph.D in Theoretical Physics (UK)
-
Founder of JMCR family office*
*JMCR family office was established in 2013, founded to manage the private assets for founder‘s family and close relations. Under the family office , JMCR Capital隽华资本 ® for investment fund and JMCR Partners隽华国际 ® for assets management, specialize in the fields of Private Equity and Quantitative Investment Strategy.
Laurence Lao, PhD
Head of Translational Medcine & Clinical Trials
Lianfeng Lin, PhD
Research and Business
Development Scientist
Renfei Wang, PhD
Vice President
Ying Su
Operation Director
Wenjia Zhou
Finance Controller
Carrie Lu
Investment Associate
Winners Select Winners ：Peer review platform formed by winning Venture Partners, EIR, Advisory Partners, Founders
Who are they
-
Top tier scientists in drug discovery and development
-
Proven successful track record from bench, IND to FDA approval
-
Senior medical R&D management expert in clinical stage
-
Senior experts in deal sourcing and verification
Founders of innovative Biotech
Their track record
Contact Us
Send us a business plan
If you have a great early-stage biotechnological or pharmaceutical project align with our investment strategy, please send your business plan to info@vivaventuresbiotech.com. We look forward to it!